Financial Performance - For the six months ended September 30, 2025, the group recorded total revenue of approximately HKD 10,500,000, compared to HKD 10,435,000 for the same period in 2024, indicating a stable revenue level [4]. - The gross profit margin for the six months ended September 30, 2025, was approximately 79.37%, an increase from 78.40% in the same period of 2024 [4]. - The group reported a loss attributable to owners of the company of approximately HKD 2,671,000 for the six months ended September 30, 2025, compared to a profit of HKD 7,602,000 in the same period of 2024, primarily due to the absence of one-time gains from the sale of subsidiaries [4]. - The company reported a basic and diluted loss per share of HKD 0.237 for the six months ended September 30, 2025, compared to earnings per share of HKD 1.349 in the same period of 2024 [6]. - The company reported a net profit of HKD 7,602,000 for the six months ended September 30, 2025, compared to a net loss of HKD 2,671,000 for the same period in 2024 [9]. - The total comprehensive income for the period was HKD 7,265,000 after accounting for total expenses [9]. - The company incurred a loss attributable to owners of approximately HKD 2,671,000 for the six months ended September 30, 2025, compared to a profit of HKD 7,602,000 for the same period in 2024, marking a significant decline [30]. Assets and Liabilities - Total assets as of September 30, 2025, amounted to HKD 20,706,000, compared to HKD 9,832,000 as of March 31, 2025, reflecting significant growth in asset value [7][8]. - Current assets increased to HKD 19,183,000 as of September 30, 2025, from HKD 8,559,000 as of March 31, 2025, indicating improved liquidity [7]. - The company's equity attributable to owners increased to HKD 19,076,000 as of September 30, 2025, compared to a negative equity of HKD 6,509,000 as of March 31, 2025 [7]. - Current liabilities decreased significantly to HKD 1,868,000 as of September 30, 2025, from HKD 16,587,000 as of March 31, 2025, improving the company's financial position [8]. - The current ratio as of September 30, 2025, was approximately 9.26, a substantial increase from 0.52 as of March 31, 2025 [38]. - The debt-to-equity ratio was not applicable as of September 30, 2025, compared to 99.19% as of March 31, 2025 [39]. Cash Flow - Cash and cash equivalents at the end of the period rose to HKD 7,519,000, up from HKD 1,630,000 at the end of September 2024 [11]. - The company experienced a cash outflow of HKD 14,463,000 from operating activities for the six months ended September 30, 2025, compared to a cash inflow of HKD 476,000 in the previous year [11]. - The company reported a net cash inflow from the rights issue amounting to approximately HKD 26,700,000 [26]. Expenses - Sales and distribution expenses increased by approximately 66.69% to HKD 2,582,000 for the current period, up from HKD 1,549,000 in the previous year, primarily due to higher spending on online promotion and marketing services [30]. - Administrative expenses decreased by approximately 7.79% to HKD 8,722,000 for the current period, compared to HKD 9,459,000 in the previous year, indicating improved cost management [30]. - The total employee cost for the review period was approximately HKD 4,154,000, down from HKD 6,699,000 in the previous year [47]. Dividends - The board of directors did not recommend the distribution of dividends for the six months ended September 30, 2025, consistent with the previous year [4]. - The company did not declare any dividends for the six months ended September 30, 2025, consistent with the previous year [27]. - The company did not recommend any dividend for the six months ended September 30, 2025, consistent with the previous year [44]. Corporate Governance - The company has complied with the corporate governance code as per GEM listing rules during the review period [63]. - The audit committee, consisting of independent non-executive directors, has reviewed the unaudited condensed consolidated results, ensuring compliance with applicable accounting standards and GEM listing rules [67]. - The company has established a remuneration committee responsible for determining the specific remuneration packages of all executive directors, including benefits and compensation [64]. - The company has a nomination and corporate governance committee that reviews the board's structure and recommends suitable candidates for board membership [65]. Strategic Developments - The company continues to focus on providing comprehensive hospital services in China, with all revenues generated from this segment [18]. - The company is strategically optimizing regional resource allocation to focus on markets with clearer long-term growth attributes, particularly in advanced medical procedures and specialized treatments [34]. - The company has submitted an application for a tertiary specialized hospital in Hainan, significantly upgrading from the previously planned secondary classification, reflecting its commitment to meet increasing clinical and comprehensive medical service demands in China [34]. - The company has signed a five-year lease for a property of 13,800 square meters in Hainan for the operation of the Hainan hospital, with an additional two-year lease for a 340 square meter medical facility [36]. - The expected issuance of the medical institution license for the Hainan hospital is anticipated in December 2025, with the operational license expected in the first half of 2026 [36]. - The company aims to leverage favorable policies and strategic advantages in Hainan to capture significant growth potential in the local healthcare market [35]. - The company is open to exploring suitable opportunities in Beijing and other regions if market conditions become more favorable, despite the ongoing contraction of its Beijing business [33]. - The company is adjusting its business deployment in response to structural changes in patient demand and service preferences in the Chinese healthcare market [33]. - The company has appointed Mr. Wang Haitao as the CEO of the Hainan hospital, bringing extensive experience in hospital management and healthcare investment [36]. Share Capital - The company issued shares during the rights issue, resulting in an increase of HKD 28,183,000 in equity [9]. - The company issued 563,649,988 new shares through a rights issue at a subscription price of HKD 0.05 per share, increasing the total issued share capital to 1,146,999,976 shares [26]. - The weighted average number of ordinary shares for calculating basic loss per share was approximately 1,127,299,976 shares for the current period, compared to 563,649,988 shares for the previous year [23]. - The company has not established any preferential rights for existing shareholders regarding the issuance of new shares [61]. - The company has not granted any stock options that remain unexercised as of the six months ending September 30, 2025 [58]. Other Information - The company has not applied any new accounting standards that have been issued but not yet effective, which would have a significant impact on its financial statements [15]. - There were no significant acquisitions or disposals of subsidiaries or associates during the review period [48]. - The company had no contingent liabilities or significant litigation as of September 30, 2025 [42]. - There were no major capital commitments as of September 30, 2025, remaining unchanged from March 31, 2025 [40]. - There were no purchases, sales, or redemptions of the company's listed securities by the company or any of its subsidiaries during the six months ending September 30, 2025 [59]. - As of September 30, 2025, there are no interests held by directors or their associates in any business that competes directly or indirectly with the group [60].
金威医疗(08143) - 2026 - 中期业绩